Nelson Teng

Dr. Nelson Teng, MD, PhD, joined GSR Ventures in 2012, with a focus on investments in healthcare and biotechnology industries. Dr. Teng serves as a managing director at an early-stage healthcare fund, Charter Life Sciences, and is the chief of gynecologic oncology at Stanford University’s School of Medicine. He has also founded several companies including women’s healthcare company Adeza Biomedical (acquired by Hologic), biotechnology company Univax Biologics (IPO on NASDAQ in 1992, then acquired by NABI), medical device company Vesta (acquired by Pfizer), and biologics company SeraCare Life Sciences (NASDAQ: SRLS). In Asia, he has been an advisor to Asian governments and Asian-based venture capital funds. Dr. Teng received a PhD in biophysics from the University of California, Berkeley, and an MD from the University of Miami.